A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
The Brighterside of News on MSN4h
Ozempic found to reduce cravings for alcohol, heavy drinkingAlcohol is responsible for a significant portion of global disease and death, contributing to 2.6 million deaths annually. It ...
Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback